Delivery Order SPE2DB22D1202-SPE2DB25FVJM9
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $71,577.02 to AmerisourceBergen Drug Corp for the supply of Boostrix TDAP vaccine in 0.5mL syringes, with an ultimate completion date of August 29, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply agreement with the DLA. The place of performance is listed as Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,109.28 to AmerisourceBergen Drug Corp for Boostrix TDAP vaccine in syringe form (0.5mL). The contract, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a firm fixed price delivery order with no set-aside designation. Performance will occur at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $75,338.45 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Boostrix TDAP vaccine in 0.5mL syringe format, with an ultimate completion date of August 18, 2025. This non-set-aside, competitively awarded contract represents a single delivery order fulfillment under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The vaccine will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Boostrix TDAP vaccine syringes (0.5ML) valued at $1,044.92 under a firm fixed price contract with an ultimate completion date of August 28, 2025. This non-set-aside award represents a single delivery order positioned as a child contract, leveraging the company's extensive pharmaceutical supply capabilities and established federal procurement relationships. The vaccine delivery will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $1,330.50 to AmerisourceBergen Drug Corp for Boostrix TDAP vaccine in 0.5ML syringes. This competitively awarded, firm fixed-price delivery order was issued on August 14, 2025, with an ultimate completion date of August 15, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Boostrix TDAP vaccine in 0.5 mL syringes, with a contract value of $9,228.10. This firm fixed-price delivery order, issued on August 25, 2025, represents a non-competitive award under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million and extending through December 2026. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Boostrix TDAP vaccine in syringe form (0.5mL) with a ceiling value of $1,064.40. This competitively awarded, firm fixed-price delivery order was issued on July 23, 2025, with an ultimate completion date of July 24, 2025. The contract utilizes no set-aside designation and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is executed under...
- The Defense Logistics Agency awarded a delivery order valued at approximately $31K to AmerisourceBergen Drug Corp for supply of Boostrix TDAP vaccine in 0.5mL syringe format, with an ultimate completion date of August 13, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. The contract was awarded on August 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,275.58 to AmerisourceBergen Drug Corp for Boostrix TDAP vaccine in syringe form (0.5mL). This competitive award, issued on June 25, 2025, with an ultimate completion date of June 26, 2025, represents a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Boostrix TDAP vaccine in 0.5ml syringe format, valued at $3,918.45 under a firm fixed-price contract type. The award was made on August 22, 2025, with an ultimate completion date of August 25, 2025. This delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVJM9Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,435.48 to AmerisourceBergen Drug Corp for the supply of Boostrix TDAP vaccine in syringe format (0.5mL). This non-set-aside contract, awarded on August 27, 2025, with an ultimate completion date of August 28, 2025, represents a firm fixed-price delivery order. The place of performance is listed as Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate headquarters and a key distribution hub for the company's federal pharmaceutical supply operations. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. As a prime vendor under this comprehensive global pharmaceutical support vehicle, AmerisourceBergen supplies a wide range of pharmaceutical products, vaccines, and medical supplies to support military healthcare programs worldwide. The vaccine delivery order reflects the company's critical role in supplying essential immunological products to the Defense Health Agency and other federal healthcare systems through the DLA's Medical Supply Chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 8/27/25 |